Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY – Get Free Report) saw strong trading volume on Thursday . 63,058 shares changed hands during mid-day trading, an increase of 140% from the previous session’s volume of 26,298 shares.The stock last traded at $78.62 and had previously closed at $78.70.
Analyst Ratings Changes
Separately, Barclays raised Sandoz Group to a “strong-buy” rating in a research report on Monday, October 13th. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy”.
Read Our Latest Stock Analysis on SDZNY
Sandoz Group Stock Performance
Sandoz Group Company Profile
Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.
The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.
Featured Articles
- Five stocks we like better than Sandoz Group
- NEW LAW: Congress Approves Setup For Digital Dollar?
- The day the gold market broke
- What a Former CIA Agent Knows About the Coming Collapse
- Your Bank Account Is No Longer Safe
- New gold price target
Receive News & Ratings for Sandoz Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sandoz Group and related companies with MarketBeat.com's FREE daily email newsletter.
